| Literature DB >> 25942703 |
Jun Hao Lei1, Liang Ren Liu1, Qiang Wei1, Shi Bing Yan2, Lu Yang1, Tu Run Song1, Hai Chao Yuan1, Xiao Lv1, Ping Han1.
Abstract
In this study, we evaluated if male circumcision was associated with lower HIV acquisition for HIV (-) males and HIV (-) females during normal sexual behavior. We performed a systematic literature search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases to identify studies that compared HIV acquisition for the circumcised and uncircumcised groups. The reference lists of the included and excluded studies were also screened. Fifteen studies (4 RCTs and 11 prospective cohort studies) were included, and the related data were extracted and analyzed in a meta-analysis. Our study revealed strong evidence that male circumcision was associated with reduced HIV acquisition for HIV(-) males during sexual intercourse with females [pooled adjusted risk ratio (RR): 0.30, 95% CI 0.24 0.38, P < 0.00001] and provided a 70% protective effect. In contrast, no difference was detected in HIV acquisition for HIV (-) females between the circumcised and uncircumcised groups (pooled adjusted RR after sensitivity analysis: 0.68, 95%CI 0.40-1.15, P = 0.15). In conclusion, male circumcision could significantly protect males but not females from HIV acquisition at the population level. Male circumcision may serve as an additional approach toward HIV control, in conjunction with other strategies such as HIV counseling and testing, condom promotion, and so on.Entities:
Mesh:
Year: 2015 PMID: 25942703 PMCID: PMC4420461 DOI: 10.1371/journal.pone.0125436
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary table of correlation of male circumcision status and HIV acquisition.
| Study/ study design | sites | population | size analyzed in cir./unc. group | follow up duration | proportion with circumcised male | HIV(+) rate in circumcised group | HIV(+) rate in uncircumcised group | Unadjusted RR | Adjusted RR(95% CI) |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Auvert2005 /RCT | South Africa | male of general population | 1546/1582 | 21mons | 49% | 0.85 per 100 pyo | 2.1 per 100 pyo | 0.40 (0.24–0.68) | 0.39 (0.23–0.66) |
| Bailey2007 /RCT | Kisumu, Kenya | HIV(-) male | 1391/1393 | 24mons | 50% | 2.1% (1.2–3.0) | 4.2% (3.0–5.4) | 0.47 (0.28–0.78) | 0.41 (0.24–0.70) |
| Gray2007 /RCT | Rakai, Uganda | HIV(-) male | 2474/2522 | 24mons | 50% | 0.66 per 100 pyo | 1.33 per 100 pyo | 0.49 (0.28–0.84) | 0.49 (0.29–0.81) |
| Cameron1989 /P. Cohort | Nairobi, Kenya | STD clinic visitors | 214/79 |
| 73% |
|
| 0.10 (0.04–0.22) | 0.12 (0.04–0.33) |
| Lavreys1999 /P. Cohort | Mombasa,Kenya | HIV(-) male | 651/95 | 20mons | 13% | 2.50 per 100 pyo | 1.8 per 100 pyo | 0.42 (0.22–0.81) |
|
| Wawer1999 /P. Cohort | Rakai, Uganda | Subgroup1(S1): HIV(-) male | 409/1635 | 20mons | 20% | 1.40 per 100 pyo |
| 0.97 (0.36–2.25) |
|
|
| Subgroup2(S2): HIV(-) male | 346/1961 | 20mons | 15% | 0.70 per 100 pyo |
| 0.45 (0.09–1.40) |
| |
| Ronaid2000 /P. Cohort | Rakai, Uganda | HIV(-) male | 908/4608 | 49mons | 16% | 1.10 per 100 pyo | 1.8 per 100 pyo | 0.61 (0.37–0.97) | 0.53(0.33–0.87)) |
| Reynolds2004 /P. Cohort | Pune, India | HIV(-) male | 191/2107 | 12mons | 8% | 0.70 per 100 pyo | 5.50 per 100 pyo | 0.13 (0.02–0.47) | 0.15 (0.04–0.62) |
| Gray2012/P. Cohort | Rakai, Uganda | HIV(-) male | 3198/402 | 4.79years | 89% | 0.50 per 100 pyo | 1.93per 100 pyo | 0.27 (0.16–0.44) | 0.27 (0.16–0.45) |
|
| |||||||||
| Wawer2009 /RCT | Rakai, Uganda | Female with HIV(+) partners | 92/67 | 24mons | 58% | 18% (17/92) | 12% (8/67) | 1.58 (0.68–3.66) | 1.49 (0.62–3.57) |
| Kapiga1998 /P. Cohort | Dar es Salaam, Tanzania | Family planning clinic visitors | 1022/22 | 34mons | 98% | 2.60 per 100 pyo | 9.20 per 100 pyo | 0.28 (0.09–0.89) | 0.29 (0.09–0.97) |
| Reynolds2006 /P. Cohort | Rakai, Uganda | Couples with HIV(+)males |
|
| 13% | 6.60 per 100 pyo | 10.3 per 100 pyo | 0.67 (0.45–1.00) |
|
| Turner2007 /P. Cohort | Zimbabwe | Family planning clinic visitors/STD clinic visitors/sex workers | 989/3249 | 24mons | 30% | 2.03 per 100 pyo | 2.96 per 100 pyo | 0.69 (0.48–0.99) | 0.78 (0.53–1.14) |
| Baeten2010/P. Cohort | 14 sites in east/southern Africa | Couples with HIV(+) males | 374/722 | 24mons | 34% | 2.72 per 100 pyo | 4.38 per 100 pyo | 0.62 (0.35–1.10) | 0.56 (0.30–1.05) |
RCT: randomised controlled trial. P. Cohort: prospective cohort study.
*Person-years of observation.
#Risk ratio is incidence rate (or hazard) ratios for RCT and Cohort shown.
&Confidence interval.
○Hazard ratio adjusted for sexual behaviour that increased slightly in the intervention group, condom use, and health-seeking behavior.
◎Hazard ratio adjusted for non-adherence to treatment and excluding four men found to be seropositive at enrolment.
⊕Rate ratio adjusted for age, marital status, and sexual risk behaviours at enrolment.
♂Adjusting factors were not achieved.
⊙Rate ratio adjusted for age, marital status, sexual partners in past year, sex for money, condom use and syphilis.
♀Rate ratio adjusted for Hindu/non-Hindu religion, level of education, living with family; and time-dependent covariates: calendar year,age group, marital status, multiple sex partners, number of female sex-worker partners (0, 1, 2–9, or10~), condom use, tattoos, and medical injections.
☆Hazard Ratio adjusted for sociodemographic characteristics at the last trial visit and time-dependent sexual behaviors during posttrial follow up.
※Hazard ratio adjusted for age and condom useage.
▽Rate ratio adjusted for age, marital status, gonorrhea/candidiasis at baseline, number of sexual partners and alcohol consumption during the follow-up period.
◇Hazard ratio adjusted for age, age at coital debut, contraceptive method, husband′s employment status, education, number of partners in past 3 months, and a product-interaction term between time and number of partners in past 3 months.
§Hazard ratio adjusted for male partner HIV-1 plasma viral load and censored at male partner antiretroviral therapy initiation.
№Dates were not available.